Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases

Sponsor
The First Affiliated Hospital with Nanjing Medical University
Study ID
NCT06124729
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases - a Single-center, Single-arm, Open-label Clinical Trail.

Key Dates

First listed
Nov 9, 2023
Start date
Dec 31, 2023
Status verified
Nov 2023
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy

Primary Outcome Measure

cCR [ Time Frame: 20 weeks ]

Central Contacts

Related Studies